BC
GHDX

Broadfin Capital’s Genomic Health, Inc. GHDX Stock Holding History

Broadfin Capital’s Portfolio GHDX Stock Details GHDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-270,400
Closed -$7M – 77
2016
Q2 		$7M Buy
+270,400
New +$7.18M 0.68% 37
2015
Q2 		– Sell
-75,000
Closed -$2.29M – 99
2015
Q1 		$2.29M Buy
+75,000
New +$2.38M 0.18% 74

Other funds holding GHDX

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Broadfin Capital's GHDX Position: Q3 2016 in Review

Broadfin Capital sold out of Genomic Health, Inc. (GHDX) in Q3 2016, closing a stake of 270,400 shares — an estimated $7M sold.

Broadfin Capital first reported a position in GHDX in Q1 2015 and held it in 2 quarters. The position peaked at $7M in Q2 2016. 134 funds tracked by Wall St. Rank hold GHDX as of Q3 2016.

  • Broadfin Capital reported no remaining Genomic Health, Inc. position as of Q3 2016 after selling out during the quarter.
  • Broadfin Capital sold 270,400 Genomic Health, Inc. shares in Q3 2016, an estimated $7M.
  • Broadfin Capital first reported a position in Genomic Health, Inc. in Q1 2015 and held it in 2 quarters.
  • Broadfin Capital's Genomic Health, Inc. position peaked at $7M in Q2 2016.
  • 134 funds tracked by Wall St. Rank held Genomic Health, Inc. as of Q3 2016.

Based on Broadfin Capital's 13F filing for Q3 2016, filed 14 Nov 2016.